Furthermore, SKOV-3 tumor xenografts in mice were shown to develop less when TRPV6 was targeted using TRPV6 peptide antagonists, supporting the idea that TRPV6 may be a key target for ovarian cancer treatments [78]. Here, TRPV6 is linked to neoplasm.